Yahoo · Oct 2, 2026
An $8 Billion Reason Why Regeneron Stock Is in Focus
Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.
SN
NASDAQ · SNY
Sanofi
Healthcare · Drug Manufacturers - General
$40.07
Down-$0.16 (-0.40%)
Updated Oct 10, 2026, 5:48 AM
SID Score
6.0/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 119.04B
- P/E ratio
- 11.2
- Dividend yield
- 5.52%
- 52-week range
- $39.18 – $52.68
- Volume
- 2.1M
- Avg. volume
- 2.95M
Price performance · SNY
SNY price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
SNY closed at $40.07 after 21 trading sessions, down 6.31% for the selected period.
- Last close
- $40.07
- Period change
- -6.31%
- Period low
- $39.51
- Period high
- $43.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $40.17 | $40.305 | $39.92 | $40.07 | 2.1M |
| Oct 8, 2026 | $40.18 | $40.265 | $39.5848 | $40.23 | 3M |
| Oct 7, 2026 | $39.94 | $40.25 | $39.72 | $40.20 | 2.08M |
| Oct 6, 2026 | $40.05 | $40.05 | $39.235 | $39.56 | 3.05M |
| Oct 5, 2026 | $39.83 | $39.88 | $39.18 | $39.51 | 3.8M |
| Oct 2, 2026 | $39.58 | $40.07 | $39.50 | $39.92 | 4.34M |
| Oct 1, 2026 | $41.85 | $41.8759 | $40.635 | $40.67 | 6.68M |
| Sep 30, 2026 | $41.35 | $41.375 | $40.96 | $41.23 | 4.3M |
| Sep 29, 2026 | $40.58 | $40.80 | $40.40 | $40.74 | 3.04M |
| Sep 28, 2026 | $40.77 | $41.24 | $40.77 | $41.18 | 2.17M |
| Sep 25, 2026 | $40.89 | $41.12 | $40.655 | $41.11 | 2.22M |
| Sep 24, 2026 | $41.225 | $41.605 | $40.905 | $40.94 | 3.07M |
| Sep 23, 2026 | $41.85 | $41.96 | $41.405 | $41.66 | 3.84M |
| Sep 22, 2026 | $42.34 | $42.62 | $42.03 | $42.51 | 3.08M |
| Sep 21, 2026 | $42.64 | $42.775 | $42.47 | $42.50 | 2.48M |
| Sep 18, 2026 | $42.75 | $42.77 | $42.34 | $42.48 | 2.24M |
| Sep 17, 2026 | $42.82 | $43.23 | $42.82 | $43.14 | 2.96M |
| Sep 16, 2026 | $42.72 | $43.00 | $42.52 | $42.59 | 2.43M |
| Sep 15, 2026 | $42.78 | $42.89 | $42.38 | $42.40 | 2.68M |
| Sep 14, 2026 | $43.70 | $43.74 | $43.015 | $43.33 | 2.33M |
| Sep 11, 2026 | $42.81 | $42.885 | $42.41 | $42.77 | 2.37M |
Latest SNY news
The latest Smart Investors Daily articles mentioning SNY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SNY research
Overview
Company profile and research snapshot.
Company profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $57.02
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Sep 21, 2026 | BERENBERG | Buy | — |
| Sep 8, 2026 | LEERINK PARTNERS | Outperform | — |
| Sep 4, 2026 | ODDO BHF | Buy | — |
| Aug 31, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Sanofi pays Regeneron up to $8B to expand immunology alliance
Regeneron will receive $1 billion upfront, with up to $7 billion more in milestones, to co-develop four next-generation antibody drug candidates
Yahoo · Oct 1, 2026
Sanofi, Regeneron broaden alliance to find their next Dupixent
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
Yahoo · Oct 1, 2026
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
